Category: Products

Felixvet Receives FDA Approval for Cefpodoxime Proxetil Tablets

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — October 30, 2025 — Felixvet is dedicated to advancing veterinary care and addressing the needs of veterinarians, pet owners and distributors. To further this commitment, Felixvet is now introducing Cefpodoxime Proxetil tablets, an antimicrobial indicated for the treatment of skin infections in dogs. Felixvet, Inc., a manufacturer based in Ireland of generic pharmaceuticals for companion animals,  established its North American headquarters in Kansas City, Missouri, in 2023.

“Felixvet is committed to providing affordable options without sacrificing quality or reliability,” said Vince Palasota, President of North America at Felixvet. “We adhere to rigorous FDA standards, ensuring safety and efficacy in every product.”

Cefpodoxime Proxetil is a broad-spectrum antibiotic, effective against a wide variety of bacteria. It is primarily prescribed for the treatment of skin infections in dogs, such as those caused by Staphylococcus and Streptococcus bacteria. It works by interfering with the production of bacterial cell walls, ultimately killing vulnerable bacteria. Cefpodoxime Proxetil is a third-generation cephalosporin, meaning it has a wider range of efficacy as compared to previous generations. 

Cefpodoxime Proxetil is easy to administer, with its single daily dosing. It is available in 100 mg and 200 mg tablets and is intended for oral use in dogs only. 

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, contact info@felixvetus.com.

About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Felixvet Receives FDA Approval for Clindamycin Hydrochloride Tablets

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — September 22, 2025 — Felixvet Inc. is proud to announce a recent FDA approval for Clindamycin Hydrochloride Tablets, an oral antibiotic approved for use in dogs to treat skin infections, abscesses, dental infections and osteomyelitis caused by susceptible bacterial strains.

“With the approval of Clindamycin Hydrochloride Tablets, we’re expanding access to a trusted treatment option that veterinarians rely on for managing common yet potentially serious infections,” said Vince Palasota, President of North America at Felixvet. “This product reflects our ongoing commitment to quality, affordability and clinical relevance.”

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis and has demonstrated activity against a broad spectrum of aerobic and anaerobic bacteria, including Staphylococcus aureus, Staphylococcus intermedius, Bacteroides fragilis and Clostridium perfringens. It is especially effective for deep-seated infections, such as those in bone or dental tissues.

The tablets are available in 25 mg, 75 mg and 150 mg strengths and are dosed every 12 hours, with duration of treatment varying based on infection type, typically a few days for acute infections and up to 28 days for osteomyelitis.

“Clindamycin is a proven, versatile therapeutic, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, contact info@felixvetus.com.

About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Felixvet Receives FDA Approval for Methimazole Coated Tablets

Posted on by developer@wearewoodruff.com

Kansas City, MO — September 19, 2025 — Felixvet Inc. has received the first FDA generic approval for Methimazole Coated Tablets, an antithyroid drug indicated for the treatment of hyperthyroidism in cats. With this milestone, Felixvet continues to advance its mission of offering high-quality, affordable medications for companion animals. The company established its North American headquarters in Kansas City, Missouri, in 2023 and aims to serve veterinarians, pet owners and distributors alike.

The U.S. Food and Drug Administration approved Methimazole Coated Tablets (ANADA 200-814) after determining the product is bioequivalent to the pioneer drug, Felimazole (NADA 141-292), originally approved in 2009. The approval followed a rigorous review of the drug’s safety and manufacturing quality.

“Felixvet is committed to meeting the clinical needs of veterinarians while offering affordable, reliable alternatives,” said Vince Palasota, President of North America at Felixvet. “Each of our products is developed to the highest regulatory standards to ensure consistency, quality and therapeutic equivalence.”

Hyperthyroidism is most commonly diagnosed in senior felines and results from an overproduction of thyroid hormones that may cause symptoms such as weight loss, increased thirst and urination, vomiting and hyperactivity. Methimazole Coated Tablets help manage this disease by inhibiting the synthesis of thyroid hormones.

Methimazole Coated Tablets are film-coated, which can aid in administration, and are supplied in 2.5 mg and 5 mg strengths for oral use. They are administered every 12 hours with dosage adjustments made in 2.5 mg increments, based on a cat’s response and veterinary guidance.

“Methimazole is an important therapy for managing feline hyperthyroidism, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, email info@felixvetus.com.

About Felixvet: 
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Felixvet Launches Carprofen Soft Chewable Tablets

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — April 2, 2025 — As part of its commitment to enhance animal health, Felixvet has successfully launched Carprofen Soft Chewable Tablets, now available through animal health distributors. Felixvet, Inc., a generic companion animal pharmaceutical manufacturer based in Ireland, established its North American headquarters in Kansas City, Missouri, in 2023.

“We are excited to announce the launch of our fifth carprofen product offering in the U.S. market,” said Vince Palasota, President of North America at Felixvet. “This development marks a significant step forward in providing quality, affordable healthcare solutions for pets without sacrificing efficacy, safety or reliability.”

Felixvet is leading the animal health market by introducing Carprofen Soft Chewable Tablets to its portfolio of carprofen products. This addition offers veterinarians five different forms of carprofen, each specifically designed to meet the diverse needs of their customers. 

“We are committed to introducing additional products that will help us become one of the leading companion animal generic drug companies globally,” states Palasota.

Carprofen Soft Chewable Tablets provide the same therapeutic benefits as other branded carprofen medications, but the new beef flavored Felixvet Soft Carprofen Chewable Tablets offer a state of the art, unique soft chewable tablet compared to the hard chewable tablet pioneer, RIMADYL®. They are easy to administer orally due to the palatable beef flavor. Felixvet’s Soft Chewable technology is based on traditional compression technology without the constraints imposed by current production processes such as extrusion or molding.

A nonsteroidal anti-inflammatory, Carprofen Soft Chewable Tablets relieve pain and inflammation associated with osteoarthritis. The tablets are therapeutically equivalent to the pioneer drug, RIMADYL®, with the same safety and efficacy. Available in three strengths, 25, 75 and 100 mg, each tablet is scored for easy and accurate dosing.

For more information, visit Felixvet.com or info@felixvetus.com.

About Felixvet: 
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com